Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ... On March 7, 2025, the company received approval from the UK’s Medicines ...

Aug 7 (Reuters) - Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals (VRTX.O), opens new tab and CRISPR Therapeutics (CRSP.BN), opens new tab ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A ... US, UK, EU, and Australia), and that these figures will continue to trend in a similar ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Read here for a discussion of Vertex Pharmaceuticals' (VRTX) strong Q2 results, potential for long-term growth, and valuation concerns in the market.